The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
Gilles A. Salles
Research Funding - Gilead Sciences
Nicole Lamanna
Research Funding - Gilead Sciences
Bipinkumar R. Amin
Research Funding - Gilead Sciences
Ralph V. Boccia
Research Funding - Gilead Sciences
Nashat Y. Gabrail
Research Funding - Gilead Sciences
Muhammad-Ali A. Zaydan
Research Funding - Gilead Sciences
Michelle Wong
Employment or Leadership Position - Gilead Sciences
Adeboye H. Adewoye
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences